=== PAGE 39 ===

COMPLETE PAGE ANALYSIS:
--------------------------------------------------
Here is the extracted text content from the PDF page, preserving its original layout and structure:

A blue horizontal banner spans across the top of the page with a thin pink vertical strip on its left edge.

**Important Safety Information (Cont.)**

**DRUG INTERACTIONS**

*   **CYP3A Inducers:** May lead to contraceptive failure and/or increase breakthrough bleeding. Avoid
    concomitant use. If concomitant use is unavoidable, use an alternative or back-up contraceptive
    method during coadministration and up to 28 days after discontinuation of the CYP3A inducer.
*   See Full Prescribing Information for additional clinically significant drug interactions.

This is not a comprehensive list of safety information related to NEXTSTELLIS.

Please See Full Prescribing Information, including BOXED WARNING.

To report SUSPECTED ADVERSE REACTIONS, call 1-844-825-8500 or report via the FDA MedWatch
Program at www.fda.gov/medwatch or 1-800-FDA-1088.

Below the reporting information, to the left, is a black circular logo with "mayne pharma" written in white lowercase letters.

38                                                                     Full Prescribing Information is available at www.Nextstellis.com
